Tag Archives: KRAS

Latest Advances Targeting Neoantigens and Developing TCR-T Cell Therapies; Ziopharm Presents Preclinical Data from Their Hotspot TCR-T Library Program; Medigene’s PRAME-Specific TCR PD1-41BB Switch Receptor Could Treat a Broad Range of Liquid and Solid Tumors; AACR 2021 Day 6

On the final day of AACR 2021 Week I, two key TCR-T platform updates were presented from Ziopharm and Medigene, while different approaches for neoantigen discovery and TCR evaluation were explored in a panel discussion. Below, Celltelligence provides insights and context for each presentation.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.